Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155123963> ?p ?o ?g. }
- W3155123963 endingPage "393" @default.
- W3155123963 startingPage "382" @default.
- W3155123963 abstract "Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials. With the US Food and Drug Administration recently granting emergency use authorizations for neutralizing mAbs in non-hospitalized patients with mild-to-moderate COVID-19, there is an urgent need to discuss the broader potential of these novel therapies and to develop strategies to deploy them effectively in clinical practice, given limited initial availability. Here, we review the precedent for passive immunization and lessons learned from using antibody therapies for viral infections such as respiratory syncytial virus, Ebola virus and SARS-CoV infections. We then focus on the deployment of convalescent plasma and neutralizing mAbs for treatment of SARS-CoV-2. We review specific clinical questions, including the rationale for stratification of patients, potential biomarkers, known risk factors and temporal considerations for optimal clinical use. To answer these questions, there is a need to understand factors such as the kinetics of viral load and its correlation with clinical outcomes, endogenous antibody responses, pharmacokinetic properties of neutralizing mAbs and the potential benefit of combining antibodies to defend against emerging viral variants. Peter Taylor and colleagues provide an overview of the neutralizing monoclonal antibody therapies that have been developed to target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss the clinical utility of these antibodies." @default.
- W3155123963 created "2021-04-26" @default.
- W3155123963 creator A5006070255 @default.
- W3155123963 creator A5025776157 @default.
- W3155123963 creator A5032261051 @default.
- W3155123963 creator A5040885240 @default.
- W3155123963 creator A5046856654 @default.
- W3155123963 creator A5082393421 @default.
- W3155123963 date "2021-04-19" @default.
- W3155123963 modified "2023-10-12" @default.
- W3155123963 title "Neutralizing monoclonal antibodies for treatment of COVID-19" @default.
- W3155123963 cites W1988676847 @default.
- W3155123963 cites W2012505332 @default.
- W3155123963 cites W2013308585 @default.
- W3155123963 cites W2029315601 @default.
- W3155123963 cites W2029503764 @default.
- W3155123963 cites W2037286123 @default.
- W3155123963 cites W2046325875 @default.
- W3155123963 cites W2057439500 @default.
- W3155123963 cites W2065307239 @default.
- W3155123963 cites W2068540171 @default.
- W3155123963 cites W2096238447 @default.
- W3155123963 cites W2098594805 @default.
- W3155123963 cites W2115217734 @default.
- W3155123963 cites W2148822770 @default.
- W3155123963 cites W2169659972 @default.
- W3155123963 cites W2256634634 @default.
- W3155123963 cites W2325881814 @default.
- W3155123963 cites W2328116798 @default.
- W3155123963 cites W2400669628 @default.
- W3155123963 cites W2418693928 @default.
- W3155123963 cites W2473595575 @default.
- W3155123963 cites W2492186718 @default.
- W3155123963 cites W2549455555 @default.
- W3155123963 cites W2572760626 @default.
- W3155123963 cites W2808754971 @default.
- W3155123963 cites W2890205877 @default.
- W3155123963 cites W2892753696 @default.
- W3155123963 cites W2939848226 @default.
- W3155123963 cites W2945819592 @default.
- W3155123963 cites W2991491848 @default.
- W3155123963 cites W3001465255 @default.
- W3155123963 cites W3001897055 @default.
- W3155123963 cites W3004318991 @default.
- W3155123963 cites W3004348779 @default.
- W3155123963 cites W3009155534 @default.
- W3155123963 cites W3009932851 @default.
- W3155123963 cites W3011398105 @default.
- W3155123963 cites W3013742505 @default.
- W3155123963 cites W3014095365 @default.
- W3155123963 cites W3016699494 @default.
- W3155123963 cites W3016900702 @default.
- W3155123963 cites W3017122459 @default.
- W3155123963 cites W3017300461 @default.
- W3155123963 cites W3017302293 @default.
- W3155123963 cites W3021590963 @default.
- W3155123963 cites W3025987322 @default.
- W3155123963 cites W3026764413 @default.
- W3155123963 cites W3032255042 @default.
- W3155123963 cites W3032394272 @default.
- W3155123963 cites W3034202401 @default.
- W3155123963 cites W3034523319 @default.
- W3155123963 cites W3034548712 @default.
- W3155123963 cites W3046724041 @default.
- W3155123963 cites W3048907206 @default.
- W3155123963 cites W3083773456 @default.
- W3155123963 cites W3086387167 @default.
- W3155123963 cites W3087924281 @default.
- W3155123963 cites W3088970599 @default.
- W3155123963 cites W3092503590 @default.
- W3155123963 cites W3093711492 @default.
- W3155123963 cites W3096658347 @default.
- W3155123963 cites W3097452637 @default.
- W3155123963 cites W3103945884 @default.
- W3155123963 cites W3104722250 @default.
- W3155123963 cites W3107068086 @default.
- W3155123963 cites W3110542218 @default.
- W3155123963 cites W3111431752 @default.
- W3155123963 cites W3113196149 @default.
- W3155123963 cites W3115009914 @default.
- W3155123963 cites W3117730334 @default.
- W3155123963 cites W3119648922 @default.
- W3155123963 cites W3121995178 @default.
- W3155123963 cites W3125712166 @default.
- W3155123963 cites W3126841810 @default.
- W3155123963 cites W3127277789 @default.
- W3155123963 cites W3129009830 @default.
- W3155123963 cites W3143907823 @default.
- W3155123963 cites W3153049682 @default.
- W3155123963 cites W3158223263 @default.
- W3155123963 cites W4210642183 @default.
- W3155123963 cites W4212838542 @default.
- W3155123963 cites W4292315834 @default.
- W3155123963 doi "https://doi.org/10.1038/s41577-021-00542-x" @default.
- W3155123963 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8054133" @default.
- W3155123963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33875867" @default.
- W3155123963 hasPublicationYear "2021" @default.
- W3155123963 type Work @default.